Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Nicholas J VogelzangSumanta K PalSameer R GhateElyse SwallowNanxin LiMiranda PeeplesMiriam L ZichlinMark K MeiselbachJose Ricardo PerezNeeraj AgarwalPublished in: Advances in therapy (2017)
Among elderly Medicare patients with advanced RCC, first-line pazopanib tretament was associated with significantly longer OS, as well as lower healthcare costs and HRU, compared with first-line sunitinib treatment.
Keyphrases
- renal cell carcinoma
- healthcare
- metastatic renal cell carcinoma
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- middle aged
- prognostic factors
- combination therapy
- community dwelling
- skeletal muscle
- metabolic syndrome
- patient reported outcomes
- insulin resistance
- weight loss
- glycemic control
- patient reported